|Beate Sander Person1 #679757|
Canada Research Chair in Economics of Infectious Diseases and Director, Health Modeling & Health Economics and Population Health Economics Research at THETA (Toronto Health Economics and Technology Assessment Collaborative).
Current Position and Professional Functions
- Canada Research Chair in Economics of Infectious Diseases
- Director, Health Modeling & Health Economics and Population Health Economics Research (PHER), THETA
- Scientist, Toronto General Hospital Research Institute
- Associate Professor and Faculty Lead HTA program, Institute of Health Policy, Management and Evaluation (IHPME), University of Toronto
- Adjunct Scientist, Public Health Ontario
- Adjunct Scientist, Institute for Clinical Evaluative Sciences
- Adjunct Faculty, Department of Mathematics and Statistics, York University
- Faculty Associate, Canadian Centre for Health Economics (CCHE)
- Editorial Board member, Medical Decision Making
- Toronto General Hospital Research Institute (TGHRI), University Health Network
- Institute of Health Policy, Management and Evaluation (IHPME), U of T
- ICES UofT, Primary Care & Population Health Research Program
- Public Health Ontario (PHO)
Education and Training
- Beate completed her degree in Nursing (RN) in Germany and received postgraduate degrees in Business Administration (MBA) from Germany, Economics of Development (MEcDev) from the Australian National University, a Doctorate in Health Services Research (PhD) from the University of Toronto, and postdoctoral training in Public Health Policy.
Research Interests and Expertise
- Dr. Sander’s areas of expertise include health economics, decision analysis and simulation, infectious disease epidemiology, and population health decision-making. Beate’s current research focuses on economic evaluation, ranging from methods development to applied research on infectious diseases. She is leading large multidisciplinary international teams evaluating Zika and West Nile virus (WNv) mitigation strategies using data-driven simulation models, and estimating the burden of infectious diseases (C.difficile, S.pneumoniae, hepatitis, WNv, Lyme disease) using linked population-based data. She has spearheaded the linkage of laboratory and reportable disease data with administrative data, enabling novel approaches to study the burden of infectious diseases. Beate has received several awards recognizing research excellence.
- Beate provides scientific advice to decision makers and serves on scientific working groups and advisory bodies, including Canada’s National Advisory Committee on Immunization (NACI), Ontario’s Universal Influenza Immunization Program (UIIP) Review, and the National West Nile virus task force.
- Dr. Sander is the Faculty Lead for the Health Technology Assessment (HTA) program at IHPME, and enjoys teaching a popular graduate course on clinical decision making and cost-effectiveness at IHPME.
- CitationsAdd new citationList by: CiterankMap
|Link Modelling the impact of extending dose intervals for COVID-19 vaccines in Canada|
Author: Austin Nam, Raphael Ximenes, Man Wah Yeung, Sharmistha Mishra, Jianhong Wu, Matthew Tunis, Beate Sander
Publication date: 10 April 2021
Publication info: medRxiv 2021.04.07.21255094
Cited by: David Price 10:38 AM 21 October 2022 GMT
Citerank: (3) 679812Jianhong WuProfessor Jianhong Wu is a University Distinguished Research Professor and Senior Canada Research Chair in industrial and applied mathematics at York University. He is also the NSERC Industrial Research Chair in vaccine mathematics, modelling, and manufacturing. 10019D3ABAB, 679880Sharmistha MishraSharmistha Mishra is an infectious disease physician and mathematical modeler and holds a Tier 2 Canadian Research Chair in Mathematical Modeling and Program Science.10019D3ABAB, 690189Man Wah YeungSenior Health Economist at the Public Health Agency of Canada.10019D3ABAB
|Excerpt / Summary|
Background: Dual dose SARS-CoV-2 vaccines demonstrate high efficacy and will be critical in public health efforts to mitigate the COVID-19 pandemic and its health consequences; however, many jurisdictions face very constrained vaccine supply. We examined the impacts of extending the interval between two doses of mRNA vaccines in Canada in order to inform deliberations of Canada’s National Advisory Committee on Immunization.
Methods: We developed an age-stratified, deterministic, compartmental model of SARS-CoV-2 transmission and disease to reproduce the epidemiologic features of the epidemic in Canada. Simulated vaccination comprised mRNA vaccines with explicit examination of effectiveness against disease (67% [first dose], 94% [second dose]), hospitalization (80% [first dose], 96% [second dose]), and death (85% [first dose], 96% [second dose]) in adults aged 20 years and older. Effectiveness against infection was assumed to be 90% relative to the effectiveness against disease. We used a 6-week mRNA dose interval as our base case (consistent with early program rollout across Canadian and international jurisdictions) and compared extended intervals of 12 weeks, 16 weeks, and 24 weeks. We began vaccinations on January 1, 2021 and simulated a third wave beginning on April 1, 2021.
Results: Extending mRNA dose intervals were projected to result in 12.1-18.9% fewer symptomatic cases, 9.5-13.5% fewer hospitalizations, and 7.5-9.7% fewer deaths in the population over a 12-month time horizon. The largest reductions in hospitalizations and deaths were observed in the longest interval of 24 weeks, though benefits were diminishing as intervals extended. Benefits of extended intervals stemmed largely from the ability to accelerate coverage in individuals aged 20-74 years as older individuals were already prioritized for early vaccination. Conditions under which mRNA dose extensions led to worse outcomes included: first-dose effectiveness < 65% against death; or protection following first dose waning to 0% by month three before the scheduled 2nd dose at 24-weeks. Probabilistic simulations from a range of likely vaccine effectiveness values did not result in worse outcomes with extended intervals.
Conclusion: Under real-world effectiveness conditions, our results support a strategy of extending mRNA dose intervals across all age groups to minimize symptomatic cases, hospitalizations, and deaths while vaccine supply is constrained.